Gad Cotter

Summary

Publications

  1. doi request reprint Predictors and Associations With Outcomes of Length of Hospital Stay in Patients With Acute Heart Failure: Results From VERITAS
    Gad Cotter
    Momentum Research, Durham, North Carolina Electronic address
    J Card Fail 22:815-22. 2016
  2. doi request reprint Increased mortality after an acute heart failure episode: new pathophysiological insights from the RELAX-AHF study and beyond
    Gad Cotter
    Momentum Research, Inc, Durham, NC, USA
    Curr Heart Fail Rep 11:19-30. 2014
  3. doi request reprint Fluid overload in acute heart failure--re-distribution and other mechanisms beyond fluid accumulation
    Gad Cotter
    Momentum Research Inc, Durham, NC 27707, USA
    Eur J Heart Fail 10:165-9. 2008
  4. ncbi request reprint The management of acute heart failure
    O Milo-Cotter
    Momentum Research Inc, 3100 Tower Boulevard, Durham, NC 27707, USA
    Panminerva Med 52:53-66. 2010
  5. doi request reprint Acute heart failure clinical drug development: from planning to proof of activity to phase III
    Gad Cotter
    Momentum Research, Inc, Durham, NC 27707, USA
    Cardiology 116:292-301. 2010
  6. pmc Vasodilators in the treatment of acute heart failure: what we know, what we don't
    Marco Metra
    Department of Experimental and Applied Medicine, University of Brescia, Italy
    Heart Fail Rev 14:299-307. 2009
  7. doi request reprint Early worsening heart failure in patients admitted with acute heart failure--a new outcome measure associated with long-term prognosis?
    Beth Davison Weatherley
    Momentum Research Inc, Durham, NC, USA
    Fundam Clin Pharmacol 23:633-9. 2009
  8. doi request reprint Design and rationale of the PROTECT study: a placebo-controlled randomized study of the selective A1 adenosine receptor antagonist rolofylline for patients hospitalized with acute decompensated heart failure and volume overload to assess treatment effect
    Beth Davison Weatherley
    Momentum Research, Inc, Durham, NC
    J Card Fail 16:25-35. 2010
  9. doi request reprint Serial high sensitivity cardiac troponin T measurement in acute heart failure: insights from the RELAX-AHF study
    G Michael Felker
    Duke Clinical Research Institute, DUMC Box 3850, Durham, NC, 27710, USA
    Eur J Heart Fail 17:1262-70. 2015
  10. doi request reprint Patient journey after admission for acute heart failure: length of stay, 30-day readmission and 90-day mortality
    Beth A Davison
    Momentum Research, Inc, 3100 Tower Boulevard, Suite 802, Durham, NC, 27707, USA
    Eur J Heart Fail 18:1041-50. 2016

Detail Information

Publications32

  1. doi request reprint Predictors and Associations With Outcomes of Length of Hospital Stay in Patients With Acute Heart Failure: Results From VERITAS
    Gad Cotter
    Momentum Research, Durham, North Carolina Electronic address
    J Card Fail 22:815-22. 2016
    ..The length of hospital stay (LOS) is important in patients admitted for acute heart failure (AHF) because it prolongs an unpleasant experience for the patients and adds substantially to health care costs...
  2. doi request reprint Increased mortality after an acute heart failure episode: new pathophysiological insights from the RELAX-AHF study and beyond
    Gad Cotter
    Momentum Research, Inc, Durham, NC, USA
    Curr Heart Fail Rep 11:19-30. 2014
    ....
  3. doi request reprint Fluid overload in acute heart failure--re-distribution and other mechanisms beyond fluid accumulation
    Gad Cotter
    Momentum Research Inc, Durham, NC 27707, USA
    Eur J Heart Fail 10:165-9. 2008
    ..In this paper we elaborate on this possible pathophysiological mechanism and review its potential causes and amplifiers...
  4. ncbi request reprint The management of acute heart failure
    O Milo-Cotter
    Momentum Research Inc, 3100 Tower Boulevard, Durham, NC 27707, USA
    Panminerva Med 52:53-66. 2010
    ..Regretfully, to date no specific targeted therapy was proven beneficial for these patients, being one of the leading reasons for the lack of improvement in AHF outcomes over the last 30 years...
  5. doi request reprint Acute heart failure clinical drug development: from planning to proof of activity to phase III
    Gad Cotter
    Momentum Research, Inc, Durham, NC 27707, USA
    Cardiology 116:292-301. 2010
    ..e. improvements in symptoms (breathlessness), the prevention of symptom recurrence, and short-term mortality, balanced by the consideration of safety signals including an estimation of absolute mortality...
  6. pmc Vasodilators in the treatment of acute heart failure: what we know, what we don't
    Marco Metra
    Department of Experimental and Applied Medicine, University of Brescia, Italy
    Heart Fail Rev 14:299-307. 2009
    ..Given the limitations of the currently available clinical trial data, we cannot recommend any specific agent as first line therapy, although nitrates in different formulations are still the most widely used in clinical practice...
  7. doi request reprint Early worsening heart failure in patients admitted with acute heart failure--a new outcome measure associated with long-term prognosis?
    Beth Davison Weatherley
    Momentum Research Inc, Durham, NC, USA
    Fundam Clin Pharmacol 23:633-9. 2009
    ..7-6.3). Early WHF is a common adverse event in patients admitted with AHF, and is associated with AHF severity and excessive 6-month mortality. WHF should be considered as a clinically important endpoint in AHF studies...
  8. doi request reprint Design and rationale of the PROTECT study: a placebo-controlled randomized study of the selective A1 adenosine receptor antagonist rolofylline for patients hospitalized with acute decompensated heart failure and volume overload to assess treatment effect
    Beth Davison Weatherley
    Momentum Research, Inc, Durham, NC
    J Card Fail 16:25-35. 2010
    ....
  9. doi request reprint Serial high sensitivity cardiac troponin T measurement in acute heart failure: insights from the RELAX-AHF study
    G Michael Felker
    Duke Clinical Research Institute, DUMC Box 3850, Durham, NC, 27710, USA
    Eur J Heart Fail 17:1262-70. 2015
    ..We examined the association between serial measurements of high-sensitivity cardiac troponin T (hs-cTnT) and outcomes in RELAX-AHF...
  10. doi request reprint Patient journey after admission for acute heart failure: length of stay, 30-day readmission and 90-day mortality
    Beth A Davison
    Momentum Research, Inc, 3100 Tower Boulevard, Suite 802, Durham, NC, 27707, USA
    Eur J Heart Fail 18:1041-50. 2016
    ..We examined predictors and associations of length of stay (LOS), 30-day post-discharge readmission and 90-day post-discharge mortality in 1990 patients enrolled in the PROTECT study...
  11. doi request reprint Worsening Heart Failure Following Admission for Acute Heart Failure: A Pooled Analysis of the PROTECT and RELAX-AHF Studies
    Beth A Davison
    Momentum Research Inc, Durham, North Carolina Electronic address
    JACC Heart Fail 3:395-403. 2015
    ..These studies conducted analyses to examine patient characteristics and outcomes associated with worsening heart failure (WHF)...
  12. pmc Permutation criteria to evaluate multiple clinical endpoints in a proof-of-concept study: lessons from Pre-RELAX-AHF
    Beth A Davison
    Momentum Research, Inc, Durham, NC, USA
    Clin Res Cardiol 100:745-53. 2011
    ..Although observing an effect on one of many endpoints due to chance is likely, observing concurrent positive trends across several outcomes by chance is usually unlikely...
  13. doi request reprint The PROTECT in-hospital risk model: 7-day outcome in patients hospitalized with acute heart failure and renal dysfunction
    CHRISTOPHER M O'CONNOR
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27710, USA
    Eur J Heart Fail 14:605-12. 2012
    ..We aimed to identify the predictors of 7-day heart failure events or death in patients hospitalized with AHF...
  14. doi request reprint Physician-determined worsening heart failure: a novel definition for early worsening heart failure in patients hospitalized for acute heart failure--association with signs and symptoms, hospitalization duration, and 60-day outcomes
    Gad Cotter
    Momentum Research, Inc, Durham, NC 27514, USA gadcotter momentum research com
    Cardiology 115:29-36. 2010
    ..To evaluate physician-determined worsening heart failure (PD-WHF) in patients admitted with acute heart failure (AHF)...
  15. doi request reprint Worsening heart failure, a critical event during hospital admission for acute heart failure: results from the VERITAS study
    Gad Cotter
    Momentum Research, Inc, Durham, NC, USA
    Eur J Heart Fail 16:1362-71. 2014
    ..Worsening heart failure (WHF) in the first 7 days after an admission for acute HF (AHF) has been proposed as a therapeutic target in several recent AHF studies and was a co-primary endpoint of the VERITAS studies...
  16. doi request reprint Early vs. late worsening heart failure during acute heart failure hospitalization: insights from the PROTECT trial
    Robert J Mentz
    Duke University Hospital, Medicine, Division of Cardiology, 2301 Erwin Road, Durham, NC 27713, USA
    Eur J Heart Fail 17:697-706. 2015
    ..The association between the time of the WHF event and the intensity of WHF therapy with outcomes is unknown...
  17. doi request reprint Impact of serial troponin release on outcomes in patients with acute heart failure: analysis from the PROTECT pilot study
    CHRISTOPHER M O'CONNOR
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA
    Circ Heart Fail 4:724-32. 2011
    ..The degree and progression of cTnT release during hospitalization of patients with AHF is unclear. We evaluated the incidence of cTnT release during AHF hospitalization and the relationship of cTnT release with outcomes...
  18. doi request reprint Patterns of leukocyte counts on admissions for acute heart failure--presentation and outcome--results from a community based registry
    Olga Milo-Cotter
    Momentum Research Inc, Durham, North Carolina 27707, USA
    Int J Cardiol 148:17-22. 2011
    ..To determine the correlation between differential white blood cell (WBC) count and characteristics and outcome of acute heart failure (AHF) syndromes...
  19. doi request reprint Rapid clinical assessment of patients with acute heart failure: first blood pressure and oxygen saturation--is that all we need?
    Olga Milo-Cotter
    Momentum Research Inc, 3100 Tower Blvd, Suite 802, Durham, NC 27707, USA
    Cardiology 114:75-82. 2009
    ..Low oxygen saturation (SaO2) and systolic blood pressure (SBP) are signs of impending respiratory and circulatory failure that can be obtained quickly in patients with AHF...
  20. doi request reprint Growth differentiation factor 15 (GDF-15) in patients admitted for acute heart failure: results from the RELAX-AHF study
    Gad Cotter
    Momentum Research Inc, 3100 Tower Boulevard, Durham, NC, 27707, USA
    Eur J Heart Fail 17:1133-43. 2015
    ..Growth differentiation factor 15 (GDF-15) was found to be upregulated in patients with chronic heart failure (HF) and associated with disease severity, however, data on patients with acute heart failure (AHF) is lacking...
  21. doi request reprint Evaluating treatment efficacy by multiple end points in phase II acute heart failure clinical trials: analyzing data using a global method
    Hengrui Sun
    Momentum Research Inc, Durham, NC, USA
    Circ Heart Fail 5:742-9. 2012
    ..To assess concomitant simultaneous effects on multiple end points using global statistical methods in phase II acute heart failure studies...
  22. doi request reprint Low lymphocyte ratio as a novel prognostic factor in acute heart failure: results from the Pre-RELAX-AHF study
    Olga Milo-Cotter
    Momentum Research, Duke University, 3100 Tower Boulevard, Durham, NC 27707, USA
    Cardiology 117:190-6. 2010
    ..Previous studies have suggested that a lower lymphocyte ratio (Ly%) in the white blood cell (WBC) differential count is related to worse outcomes in patients with acute heart failure (AHF) and other cardiovascular disorders...
  23. doi request reprint The PROTECT pilot study: a randomized, placebo-controlled, dose-finding study of the adenosine A1 receptor antagonist rolofylline in patients with acute heart failure and renal impairment
    Gad Cotter
    Momentum Research, Inc, Durham, North Carolina, USA
    J Card Fail 14:631-40. 2008
    ..Although not powered around any specific hypothesis, this pilot study was designed to identify an efficacious dose while refining inclusion criteria and end points...
  24. doi request reprint International differences in clinical characteristics, management, and outcomes in acute heart failure patients: better short-term outcomes in patients enrolled in Eastern Europe and Russia in the PROTECT trial
    Robert J Mentz
    Duke University, Durham, NC, USA
    Eur J Heart Fail 16:614-24. 2014
    ..We investigated regional differences in an international acute HF trial...
  25. doi request reprint Heart failure therapeutics on the basis of a biased ligand of the angiotensin-2 type 1 receptor. Rationale and design of the BLAST-AHF study (Biased Ligand of the Angiotensin Receptor Study in Acute Heart Failure)
    G Michael Felker
    Division of Cardiology, Duke University School of Medicine, Durham, North Carolina Electronic address
    JACC Heart Fail 3:193-201. 2015
    ..The BLAST-AHF study will assess the efficacy and safety of a novel biased ligand of the angiotensin-2 type 1 receptor in AHF. ..
  26. doi request reprint Hyponatraemia in acute heart failure is a marker of increased mortality but not when associated with hyperglycaemia
    Olga Milo-Cotter
    Momentum Research, Inc, Durham, NC 27707, USA
    Eur J Heart Fail 10:196-200. 2008
    ..Although diabetes is a common co-morbidity in heart failure, no prior study has considered the impact of serum glucose on this relationship...
  27. doi request reprint Effect of serelaxin on mode of death in acute heart failure: results from the RELAX-AHF study
    G Michael Felker
    Division of Cardiology, Duke University School of Medicine and Duke Heart Center, Durham, North Carolina Electronic address
    J Am Coll Cardiol 64:1591-8. 2014
    ..In the RELAX-AHF (Efficacy and Safety of Relaxin for the Treatment of Acute Heart Failure) study, serelaxin, the recombinant form of human relaxin-2, reduced post-discharge mortality at 180 days in selected patients with AHF...
  28. ncbi request reprint The pathophysiology of acute heart failure--is it all about fluid accumulation?
    Gad Cotter
    Duke University Medical Center, The Duke Clinical Research Institute, Durham, NC 27715, USA
    Am Heart J 155:9-18. 2008
    ....
  29. pmc Relaxin: review of biology and potential role in treating heart failure
    Sam L Teichman
    Corthera, Inc, a subsidiary of Novartis Pharmaceuticals Corp, San Mateo, CA 94402, USA
    Curr Heart Fail Rep 7:75-82. 2010
    ..Ongoing, large-scale clinical testing will provide additional insights into the potential role of relaxin in the treatment of heart failure...
  30. ncbi request reprint Diuretics - a panacea for acute heart failure? Different formulations, doses, and combinations
    Olga Milo Cotter
    Momentum Research, Inc, Durham, NC
    Heart Fail Monit 6:9-19. 2008
    ..Heart Fail Monit 2008;6(1):9-19...
  31. doi request reprint Randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of a single oral dose of vanoxerine for the conversion of subjects with recent onset atrial fibrillation or flutter to normal sinus rhythm: RESTORE SR
    Jonathan P Piccini
    Duke University, Durham, North Carolina Electronic address
    Heart Rhythm 13:1777-83. 2016
    ..Vanoxerine is an oral, 1,4-dialkylpiperazine derivative antiarrhythmic drug being evaluated for pharmacological cardioversion of atrial fibrillation (AF)...
  32. doi request reprint Hemodynamic monitoring in acute heart failure
    Gad Cotter
    Department of Cardiology, Duke University Medical Center, Durham, NC, USA
    Crit Care Med 36:S40-3. 2008
    ....